CN104906115A - Melbine and gliquidone compound sustained-release tablet and preparation method thereof - Google Patents
Melbine and gliquidone compound sustained-release tablet and preparation method thereof Download PDFInfo
- Publication number
- CN104906115A CN104906115A CN201510340287.7A CN201510340287A CN104906115A CN 104906115 A CN104906115 A CN 104906115A CN 201510340287 A CN201510340287 A CN 201510340287A CN 104906115 A CN104906115 A CN 104906115A
- Authority
- CN
- China
- Prior art keywords
- parts
- gliquidone
- metformin
- release tablet
- compound slow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a melbine and gliquidone compound sustained-release tablet and a preparation method thereof. The compound sustained-release tablet comprises the following components in parts by weight: 30-35 parts of melbine, 1-3 parts of gliquidone, 15-20 parts of sodium alginate, 0.5-1 part of magnesium stearate, 8-10 parts of lactose and 0.5-0.8 part of polysorbate. The preparation method of the compound sustained-release tablet comprises the following steps: preparing materials; pelletizing; granulating; and tabletting. The effective medicine components, namely the melbine and the gliquidone of the compound sustained-release tablet are good in synergistic effect; the effective medicine components and pharmaceutical adjuvants are low in amount; the melbine and the gliquidone can lastingly and slowly release medicines in vivo; the plasma concentration is stable and small in fluctuation, so that the administration frequency is reduced; the compliance of patients is improved; the melbine and gliquidone compound sustained-release tablet is simple in process, good in repeatability, low in cost and beneficial to reduction of product price; and industrial production is easy to realize.
Description
Technical field
The invention belongs to medical art, is specifically a kind of metformin gliquidone compound slow-release tablet and preparation method.
Background technology
Metformin hypoglycemic effect is accurate, with sulphanylureas blood sugar lowering class medicine ratio without hypoglycemic reaction, to fat and NO non-insulin-dependent diabetes mellitus people (NIDDM) is all effective, to diet alone, the person of failing to respond to any medical treatment uses this product separately, can reduce its basal plasma glucose concentration >=20% (being generally 2mmol/L or 36mg/dl).Oral or intravenous glucose tolerance test can be improved, before its blood sugar reducing function and medication, blood sugar concentration, age, the course of disease, body weight and basal insulin level are all irrelevant, first-selected type Ⅱdiabetes mellitus of failing to respond to any medical treatment for diet-treated only and physical training, particularly fat type Ⅱdiabetes mellitus.With insulin contract, can insulin dosage be reduced, prevent hypoglycemia from occurring, share with sulfonylurea blood sugar lowering, there is synergism.Pharmacodynamics comprises: 1. promote that surrounding tissue cells (muscle etc.) is to the utilization of glucose; 2. suppress gluconeogenesis function of liver, therefore reduce glycogen and export; 3. suppress intestinal wall cellular uptake glucose, different from insulin action, namely this product is without the effect impelling lipogenesis, to normal person without obvious hypoglycemic activity, therefore, does not generally cause hypoglycemia.Pharmacokinetics comprises: after oral 2h, blood drug level peaks, drug accumulation is at intestinal wall, for 10-100 times of plasma concentration, the concentration of kidney, liver and saliva is more than 2 times of plasma concentration, be not combined with plasma protein, with original shape with urine drains, removing the half-life is 90% to be eliminated in 1.7-4.5h, 12h.During patient medication, body weight alleviates usually, plasma cholesterol, triglyceride and pre-β lipoprotein level can reduce, and periphery glucose metabolism can improve.Quick releasing formulation 3 times on the oral one.
The oral sulfonylureas drugs for diabetes of the gliquidone system second filial generation, be the agent of high activity parent beta Cell of islet, the specific receptor on beta Cell of islet film is combined, and can induce and produce appropriate insulin, to reduce blood sugar concentration.Pharmacodynamics comprises: 1. promote pancreatic islet p-cells excreting insulin, and prerequisite is the function that beta Cell of islet also has certain synthesis and excreting insulin; 2. by increasing portal vein insulin level or to liver direct effect, suppressing hepatic glycogenolytic and glyconeogenesis, liver generates and exports glucose and reduces; 3. also may increase pancreas and organize utilization to the sensitivity of insulin and sugar outward.Pharmacokinetics comprises: 1. reach the highest blood drug level after oral gliquidone 2-2.5h, be namely completely absorbed very soon.2. plasma half-life is 1.5h, and metabolism is complete, and its metabolite does not have hypoglycemic activity, and the metabolite overwhelming majority is drained through biliary tract digestive system.Be applicable to unsatisfied light, the moderate non-insulin-dependent diabetes mellitus of alone diet control curative effect, patient's B cell has certain excreting insulin function, and without serious complication.This product action temperature and, can according to the state of an illness of patient adjustment dosage, less generation hypoglycemic reaction.Early stage to promote endogenous insulin secretion in treatment, after a period of time treatment, its Main Function is to improve the sensitivity of surrounding tissue to insulin.It is unique not by the medicine of renal function in current sulphanylureas oral hypoglycemic, therefore can be used for the diabetics of impaired renal function.Quick releasing formulation 3 times on the oral one.
Diabetes are a kind of take hyperglycemia as the metabolic disease of feature caused by defect of insulin secretion and/or insulin action obstacle.Persistent high blood sugar and long-term metabolic are disorderly etc. can cause body tissue's organ, particularly eye, kidney, cardiovascular and neural infringement and dysfunction thereof and exhaustion.Severe patient can cause dehydration, the acute complications such as electrolyte disturbance and acid base imbalance ketoacidosis and Hyperosmotic coma.Diabetes, once make a definite diagnosis, are namely tackled patient and are carried out diabetes education, comprise the detection of the general knowledge of diabetes, self-blood glucose and glucose in urine.The usage of hypoglycemic medicine, the observation of untoward reaction and process etc., and the performance of various complication and control.Diabetes can not be effected a radical cure at present, need to take medicine throughout one's life once suffer from diabetes, therefore how to reduce dosage and medicining times so that the compliance improving patient is current urgent problem.
Summary of the invention
For reducing dosage and the medicining times of diabetes patient, the invention provides a kind of metformin gliquidone compound slow-release tablet, this compound slow-release tablet synergy is good, after oral, in digestive tract, follow procedure discharges medicine, effective blood drug concentration in stable and lasting maintenance human body, reduce dosage and the medicining times of patient every day, improve the compliance of patient.
The present invention seeks to be realized by following technical scheme:
A kind of metformin gliquidone slow releasing tablet, component and the parts by weight of this compound slow-release tablet comprise: metformin 30 ~ 35 parts, gliquidone 1 ~ 3 part, sodium alginate 15 ~ 20 parts, magnesium stearate 0.5 ~ 1 part, lactose 8 ~ 10 parts, Polysorbate 0.5 ~ 0.8 part.
Further, a kind of metformin gliquidone compound slow-release tablet, component and the parts by weight of this compound slow-release tablet comprise: metformin 33 parts, gliquidone 2 parts, sodium alginate 18 parts, magnesium stearate 0.8 part, lactose 9 parts, Polysorbate 0.7 part.
Further, a kind of metformin gliquidone compound slow-release tablet, component and the parts by weight of this compound slow-release tablet comprise: metformin 30 parts, gliquidone 1 part, sodium alginate 15 parts, magnesium stearate 0.5 part, lactose 8 parts, Polysorbate 0.5 part.
Further, a kind of metformin gliquidone compound slow-release tablet, component and the parts by weight of this compound slow-release tablet comprise: metformin 35 parts, gliquidone 3 parts, sodium alginate 20 parts, magnesium stearate 1 part, lactose 10 parts, Polysorbate 0.8 part.
Present invention also offers a kind of preparation method of metformin gliquidone compound slow-release tablet, its preparation process comprises:
1) get the raw materials ready, get the raw materials ready according to component needed for described a kind of metformin gliquidone compound slow-release tablet and parts by weight, pulverized 80 mesh sieves respectively;
2) metformin is granulated, by metformin and sodium alginate, magnesium stearate, lactose, 9/10ths the mixing homogeneously of Polysorbate total amount, and wet granulation;
3) gliquidone is granulated, and is mixed homogeneously by gliquidone with remaining sodium alginate, magnesium stearate, lactose, Polysorbate, wet granulation;
4) granulate, by step 2), step 3) gained granule respectively granulate, cross 20 mesh sieves;
5) tabletting, by step 3) gained granule is pressed into scrobicula shape sheet by high speed double-layer high-speed tablet machine, and sheet is heavily 0.5 ~ 1g/ sheet.
Further, a preparation method for metformin gliquidone compound slow-release tablet, step 2) described metformin granulating process drying equipment is fluid bed, technological parameter is inlet temperature is 55 ~ 60 DEG C, temperature of charge is 45 ~ 50 DEG C, and leaving air temp is 35 ~ 40 DEG C.
Further, a preparation method for metformin gliquidone compound slow-release tablet, step 3) described gliquidone granulating process drying equipment is fluid bed, technological parameter is inlet temperature is 50 ~ 55 DEG C, temperature of charge is 40 ~ 45 DEG C, and leaving air temp is 30 ~ 35 DEG C.
Beneficial effect of the present invention:
1) in order to better treat type Ⅱdiabetes mellitus, the present invention adopts metformin through screening, gliquidone makes compound slow-release tablet as active drug composition.The active drug composition metformin of this compound slow-release tablet, gliquidone synergistic action effect are good, active drug composition and pharmaceutic adjuvant consumption few, quick releasing formulation consumption every day is metformin 30mg/kg, gliquidone 3mg/kg, and compound slow release preparation every day is metformin 24mg/kg, gliquidone 2.4mg/kg.This compound slow-release tablet enables metformin, gliquidone realize in vivo discharging medicine lastingly, slowly, and blood drug level is steady, fluctuates little, thus reduces administration frequency, improves patient compliance.By controlling active drug composition concentration in blood to maintain drug effect, reducing drug release and reaching peak number of times, certain protection is also had to the internal organs of patient.Present invention process is simple, and favorable reproducibility, is easy to suitability for industrialized production; Cost is low, is conducive to reducing product price.
2) compound slow-release tablet of the present invention is in the kind and consumption selection of pharmaceutic adjuvant sodium alginate, magnesium stearate, lactose, Polysorbate, ensure that effective ingredient metformin, gliquidone can realize lastingly in vivo, prevent sticking, the good evenness that sheet is heavy while slow releasing.
3) selection of present invention process ensures that effective ingredient metformin, gliquidone can realize lastingly in vivo, prevents sticking, the good evenness that sheet is heavy while slow releasing, and effective ingredient content is high.
Detailed description of the invention
According to following embodiment, the present invention may be better understood.But those skilled in the art will readily understand, concrete material proportion, process conditions and result thereof described by embodiment only should can not limit the present invention described in detail in claims yet for illustration of the present invention.
Embodiment 1
A kind of metformin gliquidone compound slow-release tablet, component and the parts by weight of this compound slow-release tablet comprise: metformin 33 parts, gliquidone 2 parts, sodium alginate 18 parts, magnesium stearate 0.8 part, lactose 9 parts, Polysorbate 0.7 part.
A preparation method for metformin gliquidone compound slow-release tablet, its preparation process comprises:
1) get the raw materials ready, get the raw materials ready according to required component and parts by weight, pulverized 80 mesh sieves respectively;
2) metformin is granulated, by metformin and sodium alginate, magnesium stearate, lactose, 9/10ths the mixing homogeneously of Polysorbate total amount, and wet granulation; Drying equipment is fluid bed, and technological parameter is inlet temperature is 55 ~ 60 DEG C, and temperature of charge is 45 ~ 50 DEG C, and leaving air temp is 35 ~ 40 DEG C;
3) gliquidone is granulated, and is mixed homogeneously by gliquidone with remaining sodium alginate, magnesium stearate, lactose, Polysorbate, wet granulation; Drying equipment is fluid bed, and technological parameter is inlet temperature is 50 ~ 55 DEG C, and temperature of charge is 40 ~ 45 DEG C, and leaving air temp is 30 ~ 35 DEG C;
4) granulate, by step 2), step 3) gained granule respectively granulate, cross 20 mesh sieves;
5) tabletting, by step 3) gained granule is pressed into scrobicula shape sheet by high speed double-layer high-speed tablet machine, and sheet is heavily 0.5g/ sheet.
Using method: every day 2 times, each 1-2 sheet, or follow the doctor's advice according to state of an illness weight situation.
Storage: shading, sealing are preserved.
Embodiment 2
A kind of metformin gliquidone compound slow-release tablet, component and the parts by weight of this compound slow-release tablet comprise: metformin 30 parts, gliquidone 1 part, sodium alginate 15 parts, magnesium stearate 0.5 part, lactose 8 parts, Polysorbate 0.5 part.
A preparation method for metformin gliquidone compound slow-release tablet, its preparation process comprises:
1) get the raw materials ready, get the raw materials ready according to required component and parts by weight, pulverized 80 mesh sieves respectively;
2) metformin is granulated, by metformin and sodium alginate, magnesium stearate, lactose, 9/10ths the mixing homogeneously of Polysorbate total amount, and wet granulation; Drying equipment is fluid bed, and technological parameter is inlet temperature is 55 ~ 60 DEG C, and temperature of charge is 45 ~ 50 DEG C, and leaving air temp is 35 ~ 40 DEG C;
3) gliquidone is granulated, and is mixed homogeneously by gliquidone with remaining sodium alginate, magnesium stearate, lactose, Polysorbate, wet granulation; Drying equipment is fluid bed, and technological parameter is inlet temperature is 50 ~ 55 DEG C, and temperature of charge is 40 ~ 45 DEG C, and leaving air temp is 30 ~ 35 DEG C;
4) granulate, by step 2), step 3) gained granule respectively granulate, cross 20 mesh sieves;
5) tabletting, by step 3) gained granule is pressed into scrobicula shape sheet by high speed double-layer high-speed tablet machine, and sheet is heavily 0.8g/ sheet.
Using method: every day 2 times, each 1-2 sheet, or follow the doctor's advice according to state of an illness weight situation.
Storage: shading, sealing are preserved.
Embodiment 3
A kind of metformin gliquidone compound slow-release tablet, component and the parts by weight of this compound slow-release tablet comprise: metformin 35 parts, gliquidone 3 parts, sodium alginate 20 parts, magnesium stearate 1 part, lactose 10 parts, Polysorbate 0.8 part.
A preparation method for metformin gliquidone compound slow-release tablet, its preparation process comprises:
1) get the raw materials ready, get the raw materials ready according to required component and parts by weight, pulverized 80 mesh sieves respectively;
2) metformin is granulated, by metformin and sodium alginate, magnesium stearate, lactose, 9/10ths the mixing homogeneously of Polysorbate total amount, and wet granulation; Drying equipment is fluid bed, and technological parameter is inlet temperature is 55 ~ 60 DEG C, and temperature of charge is 45 ~ 50 DEG C, and leaving air temp is 35 ~ 40 DEG C;
3) gliquidone is granulated, and is mixed homogeneously by gliquidone with remaining sodium alginate, magnesium stearate, lactose, Polysorbate, wet granulation; Drying equipment is fluid bed, and technological parameter is inlet temperature is 50 ~ 55 DEG C, and temperature of charge is 40 ~ 45 DEG C, and leaving air temp is 30 ~ 35 DEG C;
4) granulate, by step 2), step 3) gained granule respectively granulate, cross 20 mesh sieves;
5) tabletting, by step 3) gained granule is pressed into scrobicula shape sheet by high speed double-layer high-speed tablet machine, and sheet is heavily 1.0g/ sheet.
Using method: every day 2 times, each 1-2 sheet, or follow the doctor's advice according to state of an illness weight situation.
Storage: shading, sealing are preserved.
Embodiment 4
Release inspection of the present invention
According to Chinese Pharmacopoeia 2010 editions two annex XD drug release determination method first methods, adopting the device of dissolution method, take water as release medium, measures the release of sample obtained by embodiment 1-3 respectively.Each sample is all in 1h, 2h, 8h, 12h sampling, and detected by HPLC, metformin release (%) the results are shown in Table 1, and gliquidone release (%) the results are shown in Table 2.
Table 1
Table 2
Conclusion: metformin gliquidone compound slow-release tablet vitro release result of the present invention shows that this compound slow-release tablet has slow releasing medicine, drug level is steady, and fluctuate little feature.
Embodiment 5
Pharmacodynamic analysis of the present invention
By Wistar rat totally 20 fasting 12h, by 60mg/kg body weight lumbar injection Streptozocin (STZ) 1 time, and give high-calorie feed raising 12 weeks, successfully prepare animal model of diabetes mellitus type II, have that overweight, impaired glucose tolerance, blood fat raise, serum insulin raises and combination rate of insulin receptor reduces the feature of companion's insulin resistant, be similar to the Clinical symptoms of Patients with NIDDM.Type Ⅱdiabetes mellitus Mus stochastic averagina is divided into 2 groups, is respectively positive controls, test group.Positive controls folk prescription single dose gastric infusion metformin quick releasing formulation, 3 times on the 1st, 1 10mg/kg, gliquidone quick releasing formulation, 3 times on the 1st, 1 1mg/kg.Test group compound recipe single dose gastric infusion 2 times on the 1st, 1 dosage is metformin 12mg/kg, gliquidone 1.2mg/kg.Get blood morning every day and survey fasting blood sugar, continuous detecting 10 days.
Blood sugar test: tail venous blood sampling, 3000rpm × 10min, separation of serum, uses determination of glucose oxidase blood glucose value, and average blood sugar value the results are shown in Table 3.
Table 3
Conclusion: compound slow-release tablet active drug consumption of the present invention every day is metformin 24mg/kg, gliquidone 2.4mg/kg, being less than positive controls active drug consumption every day is metformin 30mg/kg, gliquidone 3mg/kg.Therapeutic effect aspect, compound slow-release tablet hypoglycemic effect of the present invention is faster, is better than matched group.Illustrate that metformin gliquidone compound slow-release tablet of the present invention has good slow release effect and drug effect.
Above-described embodiment is only be described the preferred embodiment of the present invention; not scope of the present invention is limited; under not departing from the present invention and designing the prerequisite of spirit; the various distortion that those of ordinary skill in the art make technical scheme of the present invention and improvement, all should fall in protection domain that claims of the present invention determines.
Claims (7)
1. a metformin gliquidone compound slow-release tablet, it is characterized in that, component and the parts by weight of this compound slow-release tablet comprise: metformin 30 ~ 35 parts, gliquidone 1 ~ 3 part, sodium alginate 15 ~ 20 parts, magnesium stearate 0.5 ~ 1 part, lactose 8 ~ 10 parts, Polysorbate 0.5 ~ 0.8 part.
2. a metformin gliquidone compound slow-release tablet, is characterized in that, component and the parts by weight of this compound slow-release tablet comprise: metformin 33 parts, gliquidone 2 parts, sodium alginate 18 parts, magnesium stearate 0.8 part, lactose 9 parts, Polysorbate 0.7 part.
3. a metformin gliquidone compound slow-release tablet, is characterized in that, component and the parts by weight of this compound slow-release tablet comprise: metformin 30 parts, gliquidone 1 part, sodium alginate 15 parts, magnesium stearate 0.5 part, lactose 8 parts, Polysorbate 0.5 part.
4. a metformin gliquidone compound slow-release tablet, is characterized in that, component and the parts by weight of this compound slow-release tablet comprise: metformin 35 parts, gliquidone 3 parts, sodium alginate 20 parts, magnesium stearate 1 part, lactose 10 parts, Polysorbate 0.8 part.
5. the preparation method of a kind of metformin gliquidone compound slow-release tablet according to any one of claim 1-4, it is characterized in that, its preparation process comprises:
1) get the raw materials ready, get the raw materials ready according to required component and parts by weight, pulverized 80 mesh sieves respectively;
2) metformin is granulated, by metformin and sodium alginate, magnesium stearate, lactose, 9/10ths the mixing homogeneously of Polysorbate total amount, and wet granulation;
3) gliquidone is granulated, and is mixed homogeneously by gliquidone with remaining sodium alginate, magnesium stearate, lactose, Polysorbate, wet granulation;
4) granulate, by step 2), step 3) gained granule respectively granulate, cross 20 mesh sieves;
5) tabletting, by step 3) gained granule is pressed into scrobicula shape sheet by high speed double-layer high-speed tablet machine, and sheet is heavily 0.5 ~ 1g/ sheet.
6. the preparation method of a kind of metformin gliquidone compound slow-release tablet according to claim 5, it is characterized in that, step 2) described metformin granulating process drying equipment is fluid bed, technological parameter is inlet temperature is 55 ~ 60 DEG C, temperature of charge is 45 ~ 50 DEG C, and leaving air temp is 35 ~ 40 DEG C.
7. the preparation method of a kind of metformin gliquidone compound slow-release tablet according to claim 5, it is characterized in that, step 3) described gliquidone granulating process drying equipment is fluid bed, technological parameter is inlet temperature is 50 ~ 55 DEG C, temperature of charge is 40 ~ 45 DEG C, and leaving air temp is 30 ~ 35 DEG C.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510340287.7A CN104906115A (en) | 2015-06-18 | 2015-06-18 | Melbine and gliquidone compound sustained-release tablet and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510340287.7A CN104906115A (en) | 2015-06-18 | 2015-06-18 | Melbine and gliquidone compound sustained-release tablet and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104906115A true CN104906115A (en) | 2015-09-16 |
Family
ID=54075836
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510340287.7A Pending CN104906115A (en) | 2015-06-18 | 2015-06-18 | Melbine and gliquidone compound sustained-release tablet and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104906115A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434387A (en) * | 2015-12-23 | 2016-03-30 | 青岛海之源智能技术有限公司 | Metformin-acipimox compound slow-release tablets and preparation method thereof |
| CN105596339A (en) * | 2015-12-23 | 2016-05-25 | 青岛海之源智能技术有限公司 | Metformin and acipimox compound composition and preparation method thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1451385A (en) * | 2002-04-18 | 2003-10-29 | 谢理峰 | Oral compound hypoglycemic medicine |
| CN1635894A (en) * | 2001-09-28 | 2005-07-06 | 太阳医药工业有限公司 | Dosage form for treatment of diabetes mellitus |
| CN101897696A (en) * | 2009-05-27 | 2010-12-01 | 北京奥萨医药研究中心有限公司 | Sugar-lowering drug composition and application thereof |
| CN104173272A (en) * | 2013-05-27 | 2014-12-03 | 无锡杰西医药科技有限公司 | Sustained release preparation of isothiocyanate compound |
-
2015
- 2015-06-18 CN CN201510340287.7A patent/CN104906115A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1635894A (en) * | 2001-09-28 | 2005-07-06 | 太阳医药工业有限公司 | Dosage form for treatment of diabetes mellitus |
| CN1451385A (en) * | 2002-04-18 | 2003-10-29 | 谢理峰 | Oral compound hypoglycemic medicine |
| CN101897696A (en) * | 2009-05-27 | 2010-12-01 | 北京奥萨医药研究中心有限公司 | Sugar-lowering drug composition and application thereof |
| CN104173272A (en) * | 2013-05-27 | 2014-12-03 | 无锡杰西医药科技有限公司 | Sustained release preparation of isothiocyanate compound |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105434387A (en) * | 2015-12-23 | 2016-03-30 | 青岛海之源智能技术有限公司 | Metformin-acipimox compound slow-release tablets and preparation method thereof |
| CN105596339A (en) * | 2015-12-23 | 2016-05-25 | 青岛海之源智能技术有限公司 | Metformin and acipimox compound composition and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2018278907B2 (en) | Composition and medicinal product for reducing body weight and body fat, and use of said product | |
| US9724374B2 (en) | Capsule containing total flavonoids of desmodium styracifolium, method for preparing the same and use | |
| CN105233300B (en) | A kind of stable vildagliptin composition and preparation method thereof | |
| CN103479635A (en) | Pharmaceutical composition used for preventing and treating non-alcoholic fatty liver disease and application thereof | |
| CN114259507A (en) | Application of Klebsiella minutissima in preparing medicine for treating and/or preventing hyperuricemia-related diseases | |
| Hwu et al. | Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study | |
| CN104906115A (en) | Melbine and gliquidone compound sustained-release tablet and preparation method thereof | |
| CN104906114A (en) | Metformin-gliquidone compound sustained-release capsule and preparation method thereof | |
| CN106619624B (en) | Application of epalrestat in preparing medicine for treating hyperuricemia and gout | |
| CA3022247C (en) | Composition for treating diabetic disease | |
| CN104001177B (en) | A kind of compound medicament composition for the treatment of type ii diabetes or metabolism syndrome | |
| CN102727894A (en) | Pharmaceutical composition for treating diabetes and its complications and application thereof | |
| CN1331470C (en) | Method for preparing high stripping-degree hautriwaic glipizide capsule | |
| CN104470514A (en) | Medicament useful for reducing blood sugar and body weight having the structure of stilbene compounds | |
| CN104487073A (en) | A method of improving liver function | |
| CN104208034B (en) | A kind of Glimepiride medicinal composition tablets, preparation method and applications | |
| CN106943408B (en) | Application of tetramethyluric acid in preventing and treating diabetes | |
| CN101695507B (en) | Medicament for treating diabetes | |
| CN105476995A (en) | Metformin-acipimox compound sustained-release capsule and preparing method | |
| CN106138025B (en) | Use of carnosic acid for treating type I diabetes | |
| CN103393707B (en) | A kind of pharmaceutical composition for the treatment of diabetes and preparation method thereof | |
| CN105434387A (en) | Metformin-acipimox compound slow-release tablets and preparation method thereof | |
| US11318153B2 (en) | Method of using Neoandrographolide for lowering blood sugar, lowering blood lipid, improving liver function and improving renal function | |
| CN105213525A (en) | A kind of Chinese medicine preparation for the treatment of diabetes and its production and use | |
| CN102085358B (en) | Application of medicament containing hirudin, hementerin and hyaluronidase |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20150916 |
|
| RJ01 | Rejection of invention patent application after publication |